Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
Influence of GLP-1-Based Pharmacotherapies on Eating Behavior, Appetite, and Energy Intake in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dakin Clarissa, Beaumont Jordan D, O Hara Beverley
Аннотация
INTRODUCTION: Although GLP-1-based pharmacotherapies achieve clinically significant weight loss, their influence on eating behavior is unknown.
METHODS: This systematic review examined the effects of GLP-1-based pharmacotherapies on eating behavior, appetite, and energy intake in adults (≥ 18 years) with overweight or obesity (BMI ≥ 25 kg/m2) without major comorbidities. MEDLINE, PsycINFO, EMBASE and Web of Science were searched on 4th November 2025. Risk of bias was assessed, and meta-analyses were conducted for energy intake and overall appetite suppression, with other outcomes synthesized qualitatively.
RESULTS: Twenty-five articles involving 4060 participants were included (64% female, mean age = 44 years, mean BMI = 36.7 kg/m2). Four studies were deemed low risk of bias. A reduction in energy intake was observed (SMD = -0.775, 95% CI = -1.21 to -0.34, p = 0.002), although heterogeneity was high (I2 = 82.7%) and the prediction interval included no effect. A small increase in appetite suppression was also observed (MD = 7.800, 95% CI = 3.74 to 11.86, p = 0.001). Qualitative findings suggested reductions in food craving and some measures of food reward. Nausea was more frequent with active treatment and may have influenced the observed effects or increased awareness of treatment allocation.
CONCLUSION: GLP-1-based pharmacotherapies may reduce short-term energy intake and appetite. However, the magnitude and consistency of these effects remain uncertain because of substantial heterogeneity, imputation of variance data, and variability in outcome assessment. Evidence relating to food craving, food preferences and other eating behaviors requires further investigation.
METHODS: This systematic review examined the effects of GLP-1-based pharmacotherapies on eating behavior, appetite, and energy intake in adults (≥ 18 years) with overweight or obesity (BMI ≥ 25 kg/m2) without major comorbidities. MEDLINE, PsycINFO, EMBASE and Web of Science were searched on 4th November 2025. Risk of bias was assessed, and meta-analyses were conducted for energy intake and overall appetite suppression, with other outcomes synthesized qualitatively.
RESULTS: Twenty-five articles involving 4060 participants were included (64% female, mean age = 44 years, mean BMI = 36.7 kg/m2). Four studies were deemed low risk of bias. A reduction in energy intake was observed (SMD = -0.775, 95% CI = -1.21 to -0.34, p = 0.002), although heterogeneity was high (I2 = 82.7%) and the prediction interval included no effect. A small increase in appetite suppression was also observed (MD = 7.800, 95% CI = 3.74 to 11.86, p = 0.001). Qualitative findings suggested reductions in food craving and some measures of food reward. Nausea was more frequent with active treatment and may have influenced the observed effects or increased awareness of treatment allocation.
CONCLUSION: GLP-1-based pharmacotherapies may reduce short-term energy intake and appetite. However, the magnitude and consistency of these effects remain uncertain because of substantial heterogeneity, imputation of variance data, and variability in outcome assessment. Evidence relating to food craving, food preferences and other eating behaviors requires further investigation.